GlobeNewswire by notified

DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers


Montrouge, France, November 9, 2023

DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers

  • Viaskin Peanut showed improvement between months 12 and 24 of treatment across all efficacy parameters. Notably, 81.3% of subjects who completed the oral food challenge reached an eliciting dose of ≥1,000 mg after 24 months of treatment.
  • 55.9% of subjects completed the oral food challenge at a cumulative dose of 3,444 mg without meeting stopping criteria.
  • Among treatment-arm subjects from EPITOPE, there were no treatment-related anaphylactic or serious treatment-related adverse events in the second year of active treatment.
  • DBV to highlight EPOPEX results in late-breaking oral abstract presentation at the American College of Allergy, Asthma, and Immunology (ACAAI) annual meeting on Saturday, November 11th at 9:35AM PT.
  • Company to host investor conference call and webcast at 5:00pm ET today, Thursday, November 9th, to discuss the results.

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced positive interim results from its ongoing Open-Label Extension (OLE) Study of EPITOPE (Phase 3 trial of Viaskin™ Peanut 250 µg [VP250] in toddlers ages 1 to 3 years), which is named EPOPEX. After completing participation in the EPITOPE study, eligible subjects could enroll in EPOPEX to receive a total of three years of Viaskin Peanut treatment. Double-blind placebo-controlled food challenges (DBPCFC) are conducted at the end of each year of treatment with safety assessed throughout the entire OLE. Importantly, all subjects remained blinded to their treatment assignment in EPITOPE until every patient completed EPITOPE and the database was locked; therefore, the decision to enter the OLE was not biased by the unblinding of the randomized treatment.

Twelve-Month EPITOPE OLE Interim Results:

  • 244 subjects were randomized to the active arm of EPITOPE with 208 completing the study. 85% of eligible subjects (175 of 208) entered the OLE with 95% (166 of 175) participating in the DBPCFC at Month 24 of Viaskin™ Peanut 250 µg (“VP250”) treatment. Similar percentages were observed for the subjects randomized to the placebo arm of EPITOPE: 92% of eligible subjects (91 of 99) entered the OLE with 86% (78 of 91) participating in the DBPCFC at Month 12 of VP 250 treatment.
  • The 175 and 91 subjects presented in the OLE cohorts (24 months and 12 months of VP250 treatment, respectively) are a subset of the subjects presented in the EPITOPE 12-month results (e.g., drop-outs, incomplete DBPCFC etc.).
  • After 24 months of VP250, all efficacy parameters demonstrated an increase in treatment response relative to the corresponding EPITOPE 12-month results:
    • 81.3% of participants reached an eliciting dose (ED) ≥1000 mg, or approximately 3 – 4 whole peanut kernels (64.2% in EPITOPE, n=244).
    • 63.8% reached an ED ≥2000 mg (37.0% in EPITOPE, n=244).
    • 55.9% completed the cumulative 3,444 mg DBPCFC without meeting stopping criteria (30.7% in EPITOPE, n=244).
    • Using the EPITOPE primary endpoint definition, 83.9% of subjects were responders (67.0% in EPITOPE, n=244).
  • Month-12 assessment of the efficacy parameters in the EPITOPE subjects (n=175) that entered the OLE further demonstrates the improvement in treatment response following an additional 12 months of treatment (24 months total)
    • At month 12, 74.7%, reached an eliciting dose (ED) ≥1000 mg relative to 81.3% at Month 24.
    • At month 12, 52.4% reached an ED ≥2000 mg relative to 63.8% at Month 24.
    • The proportion who completed the cumulative 3,444 mg DBPCFC without meeting stopping criteria was 39.5% and 55.9%, at months 12 and 24, respectively.
    • Using the EPITOPE primary endpoint definition, 77.4% were responders at Month 12 relative to 83.9% at month 24.
    • 47.2% (17 of 36) of subjects that did not meet EPITOPE responder criteria at Month 12 did meet the responder criteria at Month 24.
  • No treatment-related anaphylaxis or serious treatment-related adverse events occurred in the second year of active treatment. The frequency of local application site reaction decreased in the second year of treatment.
  • Efficacy results for subjects that entered the OLE from the placebo arm of EPITOPE (i.e., crossed-over to VP250 and received 12-months of treatment and were thus 2-4 years-old at VP250 treatment initiation): 62.7% reached an ED ≥1000 mg, 36.5% reached an ED ≥2000 mg, 28.4% completed the DBPCFC without meeting stopping criteria and 68.0% met the EPITOPE responder definition. These results were consistent with the EPITOPE VP250 arm results. The safety data for this group were consistent with what was observed in EPITOPE. There was a single event of treatment-related anaphylaxis (after 12 months of active treatment).

“We are thrilled with the results generated from the two-year open-label extension to the Phase 3 EPITOPE trial. This OLE aimed to evaluate the continued efficacy, safety, and tolerability of Viaskin Peanut in toddlers in a real-world setting,” stated Daniel Tassé, Chief Executive Officer of DBV Technologies. The data show that nearly 56% of subjects were able to consume a cumulative dose of 12 – 14 peanut kernels without meeting the pre-defined stopping criteria and more than 81% of subjects reached an eliciting dose of 3 – 4 peanut kernels.Recall that these are toddlers that began the study with an equivalent eliciting dose ranging from fractions of a peanut kernel to roughly one peanut kernel. This is a promising outcome for a community of peanut allergic toddlers where accidental exposure poses significant risk, and the current best practice – avoidance – places a daily burden on patients and families. These data further our belief that Viaskin Peanut has the potential to be the first FDA approved treatment for peanut allergic toddlers.

The interim data from the EPOPEX OLE will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, which is being held November 9-13, 2023, in Anaheim, CA. The data were submitted in as a late-breaking abstract and accepted for an oral abstract presentation.

The presentation and abstract details interim 12-month results from subjects previously enrolled in EPITOPE, a study of one year of epicutaneous immunotherapy with a patch containing 250 µg of peanut protein vs a placebo patch. The EPITOPE study resulted in a statistically significant treatment response vs placebo in 1-3-year-old peanut-allergic toddlers, as featured in a New England Journal of Medicine publication and editorial in May 2023.

“These interim data from the first 12 months of follow-up from the OLE demonstrate that Viaskin Peanut continued to generate a treatment effect beyond what was observed in EPITOPE,” stated Dr. Matthew Greenhawt, Children’s Hospital Colorado, lead author and study investigator. “As a clinician, I am pleased that Viaskin Peanut showed improvement between months 12 and 24 of treatment across all evaluated efficacy parameters. It is even more encouraging that this was achieved with no new safety signals and with fewer local application site reactions in year two versus year one. I look forward to progressing the EPITOPE OLE to its conclusion with the goal of assessing the long-term efficacy, safety, and tolerability of Viaskin Peanut.”

Late-Breaking Abstract (poster presentation):

EPOPEX, Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-allergic Toddlers: 1-year Open-Label Extension to EPITOPE

  • Presenter: Matthew C. Greenhawt, MD, MSc, MBA, FACAAI, Children’s Hospital Colorado, Anschutz Medical Campus, Aurora, CO.
  • Session: Late-breaking Oral Abstracts - Session 1: Food Allergy
  • Day: Saturday, November 11
  • Time: 9:35 – 10:00 AM (PT)
  • Location:   Exhibit Hall C – ePoster Area – LIVE Presentation Stage

On behalf of the food allergy community, we are so pleased to see the results from the open-label extension to the EPITOPE study" said Eleanor Garrow-Holding, CEO, Food Allergy and Anaphylaxis Connection Team. “Patients and families are eagerly awaiting FDA-approved options that may be appropriate for their unique medical needs and lifestyle. Viaskin Peanut, if approved, has the potential to be an efficacious and well-tolerated treatment with a promising safety profile. We look forward to DBV’s continued regulatory progress and the initiation of the COMFORT Toddlers safety study to support a future BLA submission and FDA’s potential review of this innovative product.”

Investor Conference Call and Webcast
DBV management will host an investor conference call and webcast today, November 9th, at 5:00pm EST, to discuss the EPOPEX data. This call is accessible via the below teleconferencing numbers and requesting the DBV Technologies call.

  • United States: +1-844-481-2866
  • International: +1-412-317-1859

A live webcast of the call will be available on the Investors & Media section of the Company’s website: A replay of the presentation will also be available on DBV’s website after the event.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Forward Looking Statements
This press release may contain forward-looking statements and estimates, including, but not limited to, statements regarding the therapeutic potential of Viaskin™ Peanut and EPIT™ and DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, and the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or project herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth herein can be found in DBV Technologies’ regulatory filings with the Autorité des Marchés Financiers (“AMF”), DBV Technologies’ filings and reports with the U.S. Securities and Exchange Commission (“SEC”), and future filings and reports made with the AMF and SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

Investor Contact
Katie Matthews
DBV Technologies
+1 857-529-2563

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393

Viaskin and EPIT are trademarks of DBV Technologies.


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology7.12.2023 03:30:00 CET | Press release

R&D Day Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology Details strong pipeline including Sanofi’s record 12 blockbuster opportunities under clinical evaluation: 9 innovative medicines and vaccines with €2 to 5 billion peak sales potential, and 3 ‘pipeline-in-a-product’ assets with a potential of over €5 billion peak sales Strategic transformation through R&D features potential multi-indication assets such as amlitelimab, frexalimab and the oral TNFR1si intended to address unmet patient needs in markets with low penetration of advanced therapiesEnhanced R&D focus aims to deliver a 50% increase in Phase 3 trials in 2024 and 2025 as well as 25 mid- to late-stage read-outs over the next 2 yearsAmbition to become an immunology powerhouse driven by recent and future launched pharma assets, generating over €10 billion in annual sales by 2030, in addition to the strong growth of

Bombardier Completes Redemption for All of its 7.50% Senior Notes due 20256.12.2023 23:01:00 CET | Press release

MONTRÉAL, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Bombardier Inc. (“Bombardier”) today announced that it has redeemed all of its outstanding US$380 million aggregate principal amount of its 7.50% Senior Notes due 2025 (the “Redemption Notes”), as set forth in the notice of redemption issued November 6, 2023. Payment of the redemption price and surrender of the Redemption Notes for redemption are being made through the facilities of the Depository Trust Company in accordance with their applicable procedures. This press release does not constitute an offer to sell or buy or the solicitation of an offer to buy or sell any security and shall not constitute an offer, solicitation, sale or purchase of any securities in any jurisdiction in which such offering, solicitation, sale or purchase would be unlawful. The securities mentioned herein have not been and will not be registered under the United States Securities Act of 1933, as amended, any state securities laws or the laws of any other jurisdic

CNH Industrial: Periodic Report on $1 Billion Buyback Program6.12.2023 22:30:00 CET | Press release

CNH Industrial: Periodic Report on $1 Billion Buyback Program Basildon, December 6, 2023 CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announces that under the €400 million component (the “First Component”) of its $1 billion share buyback program the Company completed transactions in the period November 27, 2023 through November 28, 2023, reported in aggregate, as set forth in the table below. After the purchases announced today and considering those previously executed under the First Component, the total invested amount in the First Component is approximately €187,597,638.20 ($203,388,077.50) or a total amount of 20,060,075 common shares purchased. DateNumber of common shares purchasedAverage price per share excluding feesConsideration excluding fees Consideration (*) excluding fees(€)(€)($) November 27,2023 1,500,000 9.3947 14,092,050.00 15,432,203.96 November 28,2023 1,000,000 9.5264 9,526,400.00 10,430,455.36 2,500,000 - 23,618,450.0025,862,659.32 (*) All translations determined fro

Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry6.12.2023 22:00:09 CET | Press release

Believed to be first ever psilocybin clinical trial for treatment of bipolar II depression LONDON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a paper in JAMA Psychiatry that demonstrates the potential for investigational COMP360 psilocybin treatment in treatment-resistant bipolar type II disorder (bipolar II). Results from the investigator-initiated open-label study were first presented at the Annual Meeting of the American College of Neuropsychopharmacology in 2022. The study, which was conducted by Dr Scott Aaronson at Sheppard Pratt, Baltimore, and funded by Compass, investigated the safety and efficacy of a single 25mg dose of COMP360 psilocybin treatment in participants with treatment-resistant bipolar II. The primary endpoint was change in Montgomery-Åsberg Depression Rating Scale (MADRS) total s Announces Commitment to Elevate Technology Leadership in Global Sustainability Efforts at COP286.12.2023 20:25:50 CET | Press release

REDWOOD CITY, California, Dec. 06, 2023 (GLOBE NEWSWIRE) --, a leading nonprofit organization championed by technology executives, today affirmed its commitment to advancing global sustainability through information technology innovation and leadership. This announcement comes as a strategic response to the ongoing COP28 United Nations Climate Change Conference, emphasizing the need for a stronger technology presence in sustainability dialogues and decision-making processes. The COP28 event underscores the urgent need for a global conversation on sustainability strategy. However, it also highlights a significant gap: the limited involvement of digital, data, and information technology leaders in these critical discussions. Floor Bleeker, Group Chief Technology Officer of Accor and member of’s European Advisory Board, is one of the technology executives participating in this year's conference. Bleeker will be speaking on a panel with ServiceNow on Dec